Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE Total Non-current Liabilities

All obligations due after more than one year.

Apogee Therapeutics, Inc.NASDAQ: APGE

Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total non-current liabilities rises 1420.5% from a year ago

Total non-current liabilities stood at $103.7M at the end of Q2 FY2026, up 1420.5% from a year earlier and up 2012.4% from the prior quarter.

Context

  • Total non-current liabilities amounted to 7.8% of total assets at the end of Q2 FY2026, up 6.7 pp from a year earlier.
  • Total non-current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +1420.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$103.7M+2012.4% QoQ
Last fiscal yearDec 2025
$5.35M-37.8% YoY
Year agoJun 2025
$6.82M+1420.5% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1420.5%——
1 year-37.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
5.35M USD
Year-over-year change
-37.8%

Total Non-current Liabilities vs competitors

How APGE compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +1420.5% is the highest of 10, against a peer median of -4.1%.
  • Total non-current liabilities amounts to 7.8% of total assets for APGE, versus a peer median of 8.7%.
APGE Competitors
Total Non-current Liabilities for APGE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$1.2B USD+38.1%+9.4%92.6%
AAPGAscentage Pharma Group InternationalDec 2025CN¥986.62M CNY-16.2%-13.8%24.9%
CELCCelcuity Inc.Jun 2026$754.13M USD+659.6%+109.4%91.1%
LEGNLegend Biotech CorporationSep 2026$119.1M USD-55.6%-30.9%7.1%
CNTACentessa Pharmaceuticals plcMar 2026$117.84M USD+0.4%+19.0%18.4%
APGEApogee Therapeutics, Inc.Jun 2026$103.7M USD+1420.5%—7.8%
IRONDisc Medicine, Inc.Sep 2026$60.88M USD+100.8%+209.4%8.7%
ZLABZai Lab LimitedJun 2026$39.17M USD-4.1%+5.5%3.6%
CGONCG Oncology, Inc. Common stockSep 2026$9.27M USD-21.0%+4.5%0.9%
XENEXenon Pharmaceuticals Inc.Sep 2026$8.19M USD-18.0%+230.2%0.7%
Peer median (excluding APGE) —-4.1%+9.4%8.7%

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents151.89M118.32M141.79M131.55M
Short-term Investments0277.14M378.86M598.64M
Net Receivables01.21M4.7M5.96M
Inventory0000
Other Current Assets57K01.74M605K
Total Current Assets152.06M398.41M529.71M741.36M
Property, Plant & Equipment (Net)02.59M13.32M14.38M
Goodwill0000
Intangible Assets0000
Long-term Investments00210.42M0
Tax Assets0000
Other Non-current Assets0401K498K181.4M
Total Non-current Assets03M224.24M195.78M
Total Assets152.06M401.4M753.95M937.13M
Account Payables418K2.14M1.07M1.22M
Short-term Debt01.1M3.23M0
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities515K17.15M22.36M3.66M
Total Current Liabilities9.98M20.56M28.56M27.91M
Long-term Debt0005.35M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities0000
Total Non-current Liabilities0933K8.6M5.35M
Total Liabilities9.98M21.49M37.16M33.25M
Common Stock2.25M01K1K
Retained Earnings(39.79M)(123.77M)(305.92M)(561.76M)
Accumulated OCI2.14M329K915K1.08M
Other Stockholders Equity0000
Minority Interest0000
Total Equity142.08M379.91M716.79M903.88M
Total Debt02.03M11.83M8.85M
Net Debt(151.89M)(116.28M)(129.96M)(122.7M)

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.